Navigation Links
Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
Date:8/11/2008

NEW YORK, Aug. 11 /PRNewswire/ -- Mergent, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the following change effective on the opening of trading on Thursday August 14, 2008: Biotest AG (Frankfurt, Germany: BIO) will replace Speedel Holding AG (SWX, Switzerland: SPPN) in the HealthShares(TM) European Drugs Index. Speedel Holding AG is being acquired by Novartis AG (SWX, Switzerland: NOVN).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080204/CLM073LOGO )

Companies included in the HealthShares(TM) European Drugs Index are headquartered in Europe and quoted on at least one European Stock Exchange that are engaged in the research, clinical development, manufacturing and commercialization of pharmaceutical products, small molecule/chemical moieties, biologics (proteins, peptides, oligoneucleotides, and cell/gene therapies) and vaccines, in all therapeutic categories, primarily intended for humans.

About Mergent

Mergent, Inc. is a leading provider of business and financial data on global publicly listed companies. Based in the U.S., the company maintains a strong global presence, with offices in New York, Charlotte, San Diego, London, Tokyo and Melbourne.

Founded in 1900, Mergent operates the longest continuously collected database of: descriptive and fundamental information on domestic and international companies; pricing and terms and conditions data on fixed income and equity securities; and corporate action data. In addition, Mergent develops and licenses equity and fixed income investment products based on its proprietary investment methodologies. Mergent-licensed products have approximately $3.5 billion in assets under management and are offered by major investment management firms. Mergent's index calculation platform is the chosen technology for some of the world's largest index companies. Its index calculation and pricing distribution protocols are used to administer index rules and distribute real-time pricing data.

For more information, please visit http://www.mergent.com and http://www.dividendachievers.com.


'/>"/>
SOURCE Mergent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Branford, Conn. (PRWEB) , ... January 11, 2017 ... ... life sciences company developing an innovative cellular response analysis platform to measure the ... a competitive Phase I Small Business Innovation Research (SBIR) grant from the National ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... platforms, announced today that the National Science Foundation (NSF) has awarded Symbios a ... funds will be used to commercialize the Symbios Tubular Plasma Reactor™ (TPR™) by ...
(Date:1/11/2017)... New Orleans, La. (PRWEB) , ... January 11, ... ... that a European business development professional has joined its team. Bernhard Bartylla will ... , “We’re working with Bernhard to introduce ACOMP and ARGEN to European ...
(Date:1/11/2017)... SAN DIEGO , Jan. 11, 2017 /PRNewswire/ ... first-in-class antibody product candidates focused on unmet medical ... Dominic Piscitelli as chief financial officer.  ... AnaptysBio,s finance strategy, as well as overseeing the ... "We are pleased to welcome Dominic to ...
Breaking Biology Technology:
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
Breaking Biology News(10 mins):